COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05226390

Breuer

mva-sars-2-s.zks@mh-hannover.de

2022-02-07

Recruiting

nonRCT

Non-randomized

Single group assignment

Open label

single-center

Prevention

inclusion criteria: the subject must not be enrolled before all inclusion criteria (including test results) are confirmed. subjects meeting all of the criteria listed below will be included in the study. signed written informed consent from subject prior to any study-related procedure and willingness to comply with treatment and follow-up procedures healthy men or women, aged ≥ 18 ≤ 60 at day of inclusion having received either primary immunization (cohort 1) with any regimen using any eu marketed sars- cov-2 vaccine or subsequently booster immunization (cohort 2) with any eu marketed mrna vaccine at least 3 months prior to enrollment adults with sars-cov-2 specific igg concentration between 10 ru/ml and 1200 ru/ml determined by anti-sars-cov-2-quantivac-elisa (igg) males or non-pregnant, non-lactating females of child-bearing potential with negative pregnancy test at screening who agree to comply with the applicable contraceptive requirements of the protocol (section 3.4) from at least 14 days prior to vaccination and during the entire duration of the study. or females without child-bearing potential defined as follows: at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or hysterectomy or uterine agenesis or ≥ 50 years and in postmenopausal state > 1 year or < 50 years and in postmenopausal state > 1 year with serum fsh > 40 iu/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening normal pulmonary function: fev1 predicted ≥ 80% and fev1/fvc > 70% body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening subject is capable of understanding the investigational nature, potential risks and benefits of the clinical trial

subjects are excluded from the study if any of the following criteria are met at screening or on dosing day. previous mva or rmva vaccination known allergy to the components of the sars-cov-2 vaccine product as chicken proteins or history of life-threatening reactions to vaccine containing the same substances known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine any laboratory value outside the reference range that the investigator considers to be of clinical relevance; safety laboratory screening evaluation can be repeated a maximum of two times any finding in the medical history and physical examination deviating from normal and assessed as clinically relevant by the investigator evidence in the subject's medical history or in the medical examination that might influence the absorption, distribution, metabolism or excretion of the investigational medicinal product current smoking/ vaping or smoking /vaping in the previous year. clinically relevant findings in ecg any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes asthma, chronic obstructive pulmonary disease or other lung disease respiratory tract infection in the 4 weeks prior to study treatment any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child known intolerance to medication used during bronchoscopy, i.e. midazolam and lidocaine. treatment with ß-adrenoceptor antagonists alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males) drug abuse or positive drug screening any positive result for hiv1/2, hcv antibody or hbs antigen testing moderate or severe illness and/or fever >38 °c within 1 week prior to vaccination history of blood donation within 60 days of enrollment or plans to donate within the treatment phase participation in a clinical trial or use of an investigational product within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study investigator or employee of the study site or sponsor with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, natural or adopted child) of the investigator or employee with direct involvement in the proposed study

1

Hannover Medical School

18

60

Germany

Healthy volunteers

N/A

30

Change from baseline of pulmonary function associated with MVA-SARS-2-ST;Change from baseline of pulmonary function associated with MVA-SARS-2-ST;Change from baseline of pulmonary function associated with MVA-SARS-2-ST;Change from baseline of pulmonary function associated with MVA-SARS-2-ST;Change of safety laboratory measures associated with MVA-SARS-2-S;Occurrence of serious adverse events (SAE) associated with MVA-SARS-2-ST;Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST;Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST;Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST;Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST;Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST;Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST;Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST;Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST;Occurrence of unsolicited adverse events (AE) associated with MVA-SARS-2-ST;The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST;The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST;The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST;The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST;The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST;The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST;The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST;The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST

None

Phase 1

[{"arm_notes": " 1 x 107 IU/dose;inhaled", "treatment_id": 2159, "treatment_name": "Mva-sars-2-st", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}]